NEW YORK, November 16, 2016 /PRNewswire/ --
On Tuesday, all three benchmark US indices were trading positively at the close of the markets. The bullish trend was reflected by broad-based gains in the US markets which saw eight out of nine sectors ending the trading session in green. Looking at yesterday's stock markets performance, Stock-Callers.com lined-up these four Biotech equities for review today: Alexion Pharmaceuticals Inc. (NASDAQ: ALXN), Progenics Pharmaceuticals Inc. (NASDAQ: PGNX), Omeros Corporation (NASDAQ: OMER), and Chimerix Inc. (NASDAQ: CMRX). Download the free research reports on these stocks today:
New Haven, Connecticut headquartered Alexion Pharmaceuticals Inc.'s stock advanced 1.24%, to close the day at $120.36. The stock recorded a trading volume of 2.12 million shares, which was above its three months average volume of 1.99 million shares. Alexion Pharma's shares have advanced 0.74% in the last one month. Shares of the Company, which develops and commercializes life-transforming therapeutic products, are trading 3.78% and 10.43% below its 50-day and 200-day moving averages, respectively. Additionally, the stock traded at a PE ratio of 73.98 and has a Relative Strength Index (RSI) of 45.61.
On November 3rd, 2016, research firm Deutsche Bank initiated a 'Buy' rating on the Company's stock, issuing a target price of $164 per share. See our free and comprehensive research report on ALXN at:
Tarrytown, New York-based Progenics Pharmaceuticals Inc.'s stock finished Tuesday's session 3.47% higher at $7.76 with a total volume of 2.78 million shares traded. Over the last one month and the previous three months, Progenics Pharma's shares have surged 35.66% and 13.95%, respectively. Furthermore, the stock has gained 17.93% in the past one year. Shares of the Company, which develops medicines for oncology in the US and internationally, are trading at a PE ratio of 49.74. The Company's shares are trading above its 50-day and 200-day moving averages by 28.22% and 46.09%, respectively. Progenics Pharma's stock has an RSI of 76.65.
On October 27th, 2016, research firm Aegis Capital initiated a 'Buy' rating on the Company's stock. PGNX free research report PDF is just a click away at:
On Tuesday, shares in Seattle, Washington-based Omeros Corp. recorded a trading volume of 1.16 million shares, which was higher than their three months average volume of 613,480 shares. The stock ended the day 2.15% higher at $13.75. Omeros' stock has surged 80.92% in the last one month, 21.90% in the previous three months and 0.22% in the past one year. The Company is trading above its 50-day and 200-day moving averages by 38.28% and 18.61%, respectively. Furthermore, shares of Omeros, which discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system, have an RSI of 78.56.
On November 10th, 2016, research firm Needham reiterated its 'Buy' rating on the Company's stock with a decrease of the target price from $28 a share to $24 a share. Sign up for your complimentary report on OMER at:
On Tuesday, shares in Durham, North Carolina headquartered Chimerix Inc. ended the session 1.21% lower at $4.89 with a total volume of 338,765 shares traded. Chimerix's shares have gained 6.07% in the last one month and 14.25% in the previous three months. The stock is trading 0.02% below its 50-day moving average and 0.80% below its 200-day moving average. Moreover, shares of the Company, which discovers, develops, and commercializes oral antivirals in the areas of unmet medical needs in the US, have an RSI of 58.23. Register for free on Stock-Callers.com and download the latest research report on CMRX at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: email@example.com Phone number: +44 330 808 3765 Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA
Subscribe to our Free Newsletters!